New research shows added benefits of Ozempic
The study was carried out over five years.
A major study has found weight loss injections could also reduce the risk of cardiovascular disease.
This was the largest piece of research into Semaglutide so far, with more than 17-thousand participants from over 40 countries taking part.
It found the drug - which is sold under the brand names Ozempic and Wegovy - showed significant weight loss for at least four years.
It also reduced the risks of heart attacks, strokes and heart failure by 20 percent - even if the patients lost no weight.
But surgeon, Dr Karan Rajan, says it's not suitable for everyone:
"When someone who doesn't require it for, you know, prolonging their life or prolonging their quality of life, if someone is just taking it to have a quick weight loss or get a six-pack before their wedding or photoshoot, that's not the right reasons to be taking a medication like this."
